


Dabigatran etexilate mesylate

Cat. No.:	HY-10274A		
CAS No.:	872728-81-9		
Molecular Formula:	C ₃₅ H ₄₅ N ₇ O ₈ S		
Molecular Weight:	723.84		
Target:	Others		
Pathway:	Others		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (69.08 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		1.3815 mL	6.9076 mL	13.8152 mL
		5 mM		0.2763 mL	1.3815 mL	2.7630 mL
		10 mM		0.1382 mL	0.6908 mL	1.3815 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (3.45 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (3.45 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (3.45 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	Dabigatran etexilate mesylate (BIBR 1048MS) is an orally active prodrug of Dabigatran. Dabigatran etexilate mesylate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation ^[1] .
In Vivo	Dabigatran etexilate mesylate (BIBR 1048MS; oral; 10, 20 and 50 mg/kg for rats and 1, 2.5 and 5 mg/kg for monkeys) has dose- and time-dependent anticoagulant effects and has maximum effects between 30 and 120 min after

administration, respectively^[1].

Dabigatran etexilate mesylate maximally and significantly prolongs partial thromboplastin time (aPTT) to 25.2, 38.4 and 78.3 s in 30 min after 10, 20 and 50 mg/kg oral doses, respectively^[1].

Dabigatran etexilate mesylate maximally prolongs the aPTT to 34.3 s, 44.0 s, and 63.0 s, respectively, 2h after 1, 2.5 or 5 mg/kg doses in the monkey^[1].

Animal Model:	Male rats (280-350 g) and rhesus monkeys of either sex (3-8 kg) ^[1]
Dosage:	10, 20 and 50 mg/kg for rats and 1, 2.5 and 5 mg/kg for monkeys
Administration:	Oral
Result:	Had dose- and time-dependent anticoagulant effects.

CUSTOMER VALIDATION

- *Biochem Pharmacol.* 2016 Nov 1;119:76-84.
- *J Chromatogr Sci.* 2016 Jul 29;54(9):1648-1651.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Wiene W, et al. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. *Thromb Haemost.* 2007 Jul;98(1):155-62.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA